{"id":4997,"date":"2025-11-03T00:54:36","date_gmt":"2025-11-03T08:54:36","guid":{"rendered":"https:\/\/wrwofficial.com\/index.php\/2025\/11\/03\/an-alzheimers-pill-appears-to-protect-some-in-a-high-risk-population-shots\/"},"modified":"2025-11-03T00:54:42","modified_gmt":"2025-11-03T08:54:42","slug":"an-alzheimers-pill-appears-to-protect-some-in-a-high-risk-population-shots","status":"publish","type":"post","link":"https:\/\/wrwofficial.com\/index.php\/2025\/11\/03\/an-alzheimers-pill-appears-to-protect-some-in-a-high-risk-population-shots\/","title":{"rendered":"An Alzheimer\u2019s pill appears to protect some in a high-risk population : Shots"},"content":{"rendered":"

<\/p>\n

\n
\n
\n <\/picture>\n<\/div>\n
\n
\n
\n

\n Scientists are taking a second look at a drug for Alzheimer’s that may help patients who are particularly at risk of developing the disease.
\n <\/p>\n

Jorg Greuel\/Photodisc\/Getty Images<\/p>\n

<\/b>
\n hide caption<\/b><\/b>\n <\/p>\n<\/p><\/div>\n

toggle caption<\/b><\/b>\n <\/div>\n

<\/p>\n

Jorg Greuel\/Photodisc\/Getty Images<\/p>\n

<\/span>\n<\/div>\n<\/p><\/div>\n

In April, the future was looking bleak for an experimental Alzheimer’s drug called valiltramiprosate, or ALZ-801.<\/p>\n

Researchers had just released topline results<\/u><\/a> of a study of more than 300 people age 50 or older, who were genetically predisposed to Alzheimer’s. Overall, those who got the drug did no better than those given a placebo.<\/p>\n

\n
\n \"Myra<\/picture><\/a> <\/p>\n

\n <\/div>\n

\n <\/div>\n

<\/p>\n

But in September, a closer look<\/u><\/a> at the results revealed benefits for a subgroup of 125 people who had only mild memory problems when they started taking the drug. <\/p>\n

Those participants, initially diagnosed with mild cognitive impairment rather than mild dementia, “showed very meaningful responses,” says Dr. Susan Abushakra, chief medical officer of Alzheon, the drug’s maker.<\/p>\n

By one measure, the drug slowed cognitive decline by 52% in people with mild cognitive impairment. That result appears comparable with benefits from the two Alzheimer’s drugs now on the market: lecanemab<\/u><\/a> and donabemab<\/u><\/a>.<\/p>\n